Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments.
Ontology highlight
ABSTRACT: A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD). In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based
SUBMITTER: Lin E
PROVIDER: S-EPMC8553527 | biostudies-literature | 2021 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA